trial
as of 2026-07-01Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics
NCTId NCT00628420
at a glance
Phase 1 · Completed
Enrollment 45 (actual)
Sponsored by University of Texas Southwestern Medical Center
Primary completion 2006-11
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
45 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2005-01
Primary completion
2006-11
Eligibility
ALL · 20 Years · 50 Years
Interventions & indications
Drugs
Sponsors
University of Texas Southwestern Medical CenterLead Sponsor
Stanley Medical Research InstituteCollaborator
ACADIA Pharmaceuticals Inc.Collaborator
Sites
2 total
Dallas, United StatesDallas, United States
Facts & assertions
4 sourced
Enrollment
45
Phase
PHASE1
Primary Completion Date
2006-11
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
indication